|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 39/00 | (2006.01) |
| C07K 16/24 | (2006.01) |
| (11) | Number of the document | 3191120 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15767597.6 |
| Date of filing the European patent application | 2015-09-08 | |
| (97) | Date of publication of the European application | 2017-07-19 |
| (45) | Date of publication and mention of the grant of the patent | 2024-04-10 |
| (46) | Date of publication of the claims translation | 2024-07-25 |
| (86) | Number | PCT/IB2015/056871 |
| Date | 2015-09-08 |
| (87) | Number | WO 2016/038538 |
| Date | 2016-03-17 |
| (30) | Number | Date | Country code |
| 201462048512 P | 2014-09-10 | US |
| (72) |
MPOFU, Shephard , CH
RICHARDS, Hanno , CH
LIGOZIO, Gregory , US
|
| (73) |
NOVARTIS AG ,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | IL-17 antagonistų panaudojimas struktūrinio pažeidimo progresavimui slopinti, sergant psoriaziniu artritu |
| USE OF IL-17 ANTAGONISTS TO INHIBIT THE PROGRESSION OF STRUCTURAL DAMAGE IN PSORIATIC ARTHRITIS PATIENTS |
| Payment date | Validity (years) | Amount | |
| 2025-08-25 | 11 | 289.00 EUR |
| 2026-09-08 |